Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis

References

• Hulka BS. Epidemiologic analysis of breast and gynecological cancers. Prog Clin Biol Res 1997;396:17–29
   PubMedGoogle Scholar
• Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   Google Scholar
• Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606–16
   PubMed Web of Science ®Google Scholar
• Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218–26
   PubMed Web of Science ®Google Scholar
• Guthrie JR, Lehert P, Dennerstein L, et al. The relative effect of endogenous estradiol and androgens on menopausal bone loss: a longitudinal study. Osteoporos Int 2004;15:881–6
   PubMed Web of Science ®Google Scholar
• Rapuri PB, Gallagher JC, Haynatzki G. Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women. [erratum appears in J Clin Endocrinol Metab 2005;90:1711]. J Clin Endocrinol Metab 2004;89: 4954–62
   Google Scholar
• Zmuda JM, Cauley J, Ljung BM, et al. Bone mass and breast cancer risk in older women: differences by stage at diagnosis. J Natl Cancer Inst 2001;93:930–6
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Center JR, Eisman JA. Association between breast cancer and bone mineral density: the Dubbo Osteoporosis Epidemiology Study. Maturitas 2000;36:27–34
   Google Scholar
• Ganry O, Baudoin C, Fardellone P, et al. Bone mass density and risk of breast cancer and survival in older women. Eur J Epidemiol 2004;19:785–92
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 1997;336:611–17
   PubMed Web of Science ®Google Scholar
• Ganry O, Peng J, Dubreuil A. Is there a reduced risk of breast cancer among women with hip fractures? Eur J Epidemiol 1999;15:313–15
   Google Scholar
• Kerlikowske K, Shepherd J, Creasman J, et al. Are breast density and bone mineral density independent risk factors for breast cancer? J Natl Cancer Inst 2005;97:368–74
   PubMed Web of Science ®Google Scholar
• Buist DS, LaCroix AZ, Barlow WE, et al. Bone mineral density and breast cancer risk in postmenopausal women. J Clin Epidemiol 2001;54:417–22
   PubMed Web of Science ®Google Scholar
• van der Klift M, de Laet CE, Coebergh JW, et al. Bone mineral density and the risk of breast cancer: the Rotterdam Study. Bone 2003;32:211–16
   PubMed Web of Science ®Google Scholar
• Santen RJ, Boyd NF, Chlebowski RT, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Rel Cancer 2007;14:169–87
   PubMed Web of Science ®Google Scholar
• Cauley J, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125–34
   PubMed Web of Science ®Google Scholar
• Martino S, Cauley JA, Barrett-Connor E, et al. Continuing Outcomes Relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751–61
   Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Hanson J. Standardization of femur BMD. J Bone Miner Res 1997;12:1316–17
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Black DM, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trial. Bone 2003;33:293–300
   PubMed Web of Science ®Google Scholar
• World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series No. 843, Geneva, 1994
   Google Scholar
• Cauley J, Lucas FL, Kuller LH, et al. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 1996;276:1404–8
   PubMed Web of Science ®Google Scholar
• Buist DS, LaCroix AZ, Barlow WE, et al. Bone mineral density and endogenous hormones and risk of breast cancer in postmenopausal women (United States). Cancer Causes Control 2001;12:213–22
   PubMed Web of Science ®Google Scholar